Indian drug regulator rejects Sputnik for direct phase-3 clinical trials advising to carry out a phase-2 trial on Indian subjects first because the number of people who had received the vaccine for an initial (phase-1/2) trial in Russia was too small https://t.co/HldTo3ETgw
— Yusuf Unjhawala 🇮🇳 (@YusufDFI) October 8, 2020